Estimation of COVID-19 vaccine effectiveness against hospitalisation in individuals aged ≥ 65 years using electronic health registries; a pilot study in four EU/EEA countries, October 2021 to March 2022.
Sentís, Alexis; Kislaya, Irina; Nicolay, Nathalie; Meijerink, Hinta; Starrfelt, Jostein; Martínez-Baz, Iván; Castilla, Jesús; Nielsen, Katrine Finderup; Hansen, Christian Holm
; Emborg, Hanne-Dorthe; +6 more...Nardone, Anthony; Derrough, Tarik; Valenciano, Marta; Nunes, Baltazar; Monge, Susana; and VEBIS-Lot4 working group
(2022)
Estimation of COVID-19 vaccine effectiveness against hospitalisation in individuals aged ≥ 65 years using electronic health registries; a pilot study in four EU/EEA countries, October 2021 to March 2022.
Eurosurveillance, 27 (30).
ISSN 1560-7917
DOI: 10.2807/1560-7917.ES.2022.27.30.2200551
; Emborg, Hanne-Dorthe; +6 more...Nardone, Anthony; Derrough, Tarik; Valenciano, Marta; Nunes, Baltazar; Monge, Susana; and VEBIS-Lot4 working group
(2022)
Estimation of COVID-19 vaccine effectiveness against hospitalisation in individuals aged ≥ 65 years using electronic health registries; a pilot study in four EU/EEA countries, October 2021 to March 2022.
Eurosurveillance, 27 (30).
ISSN 1560-7917
DOI: 10.2807/1560-7917.ES.2022.27.30.2200551
By employing a common protocol and data from electronic health registries in Denmark, Navarre (Spain), Norway and Portugal, we estimated vaccine effectiveness (VE) against hospitalisation due to COVID-19 in individuals aged ≥ 65 years old, without previous documented infection, between October 2021 and March 2022. VE was higher in 65-79-year-olds compared with ≥ 80-year-olds and in those who received a booster compared with those who were primary vaccinated. VE remained high (ca 80%) between ≥ 12 and < 24 weeks after the first booster administration, and after Omicron became dominant.
-
picture_as_pdf - Sentis_etal_2022_Estimation-of-covid-19-vaccine.pdf
-
subject - Published Version
-
- Available under Creative Commons: Attribution 4.0
Downloads